{"questions":[{"id":"open_question-3fc3ac93-718e-418f-a2ea-980d556b8247","artifact_type":"open_question","title":"Are there safety concerns about enhancing synaptic adhesion in a system where over-connectivity could promote excitotoxicity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:38.809065+00:00","updated_at":"2026-04-26T03:29:38.809065+00:00"},{"id":"open_question-be6c52ad-34f0-415a-b93e-e83e4bb65302","artifact_type":"open_question","title":"Can NRXN-NLGN dysfunction be detected presymptomatically, enabling preventive intervention?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:38.754198+00:00","updated_at":"2026-04-26T03:29:38.754198+00:00"},{"id":"open_question-21cbb04b-13de-4d42-a304-e3db25f755bd","artifact_type":"open_question","title":"What is the optimal approach: enhancing existing complexes, replacing lost components, or building artificial bridges?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:38.642106+00:00","updated_at":"2026-04-26T03:29:38.642106+00:00"},{"id":"open_question-b42f9d3b-4164-4089-bd54-858c58240f7e","artifact_type":"open_question","title":"Cell-type specificity** — Can we achieve neuron-specific targeting?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:47.224720+00:00","updated_at":"2026-04-26T03:29:47.224720+00:00"},{"id":"open_question-77868f83-fea2-487d-a259-6a39d315552d","artifact_type":"open_question","title":"Can we develop therapies that selectively target pathological condensates?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:37.962461+00:00","updated_at":"2026-04-26T03:29:37.962461+00:00"},{"id":"open_question-b27b4754-3e76-40b9-bef6-4c595b87ca5f","artifact_type":"open_question","title":"What determines the transition from physiological to pathological phase separation?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:37.902955+00:00","updated_at":"2026-04-26T03:29:37.902955+00:00"},{"id":"open_question-5688f748-770c-4e5b-9b97-0742cfab39b7","artifact_type":"open_question","title":"Combination therapy:** Optimal partners?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:37.694454+00:00","updated_at":"2026-04-26T03:29:37.694454+00:00"},{"id":"open_question-0c962161-64b7-4f98-8f0a-9b0e92aee8fe","artifact_type":"open_question","title":"Therapeutic timing:** When is intervention most effective?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:37.633042+00:00","updated_at":"2026-04-26T03:29:37.633042+00:00"},{"id":"open_question-b310c5e5-1b4b-4d28-8f38-f8425ba6b254","artifact_type":"open_question","title":"Cellular context**: What determines microglial response?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:45.886155+00:00","updated_at":"2026-04-26T03:29:45.886155+00:00"},{"id":"open_question-mechanisms-psp-oral-health-dental-manifestations-75bfde89","artifact_type":"open_question","title":"Novel anticholinergics","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-092e8434-7b62-42b3-8653-70d647fa8b5a","artifact_type":"open_question","title":"Strain identification**: How do strains determine phenotypes?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:44.776459+00:00","updated_at":"2026-04-26T03:29:44.776459+00:00"},{"id":"open_question-6db5daa7-bec3-4ca5-b6f5-7c6a2d10a4e1","artifact_type":"open_question","title":"Initiating events**: What triggers the first misfolding?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:44.718340+00:00","updated_at":"2026-04-26T03:29:44.718340+00:00"},{"id":"open_question-23517227-1170-4b35-bb3a-b0d9c88e1cd5","artifact_type":"open_question","title":"Are TLOs causative or consequential?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:59.852607+00:00","updated_at":"2026-04-26T03:26:59.852607+00:00"},{"id":"open_question-3a3de2dd-0dac-41d8-a336-9c45f3457134","artifact_type":"open_question","title":"Can TLOs be reversed?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:26:59.917577+00:00","updated_at":"2026-04-26T03:26:59.917577+00:00"},{"id":"open_question-b82abc49-117c-4b78-9114-8d476d9e3820","artifact_type":"open_question","title":"Can zombosomes be detected in cerebrospinal fluid or blood?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:38.628356+00:00","updated_at":"2026-04-26T03:27:38.628356+00:00"},{"id":"open_question-307dba23-d713-4fb5-bc6d-8ac9ce55b2ec","artifact_type":"open_question","title":"Is it specific to certain astrocyte subtypes?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:38.909946+00:00","updated_at":"2026-04-26T03:27:38.909946+00:00"},{"id":"open_question-7c549cf0-114e-45a3-931d-fea948b7a789","artifact_type":"open_question","title":"What cellular stress signals are required?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:38.965544+00:00","updated_at":"2026-04-26T03:27:38.965544+00:00"},{"id":"open_question-0457b922-306f-4798-89fe-796afea48a8d","artifact_type":"open_question","title":"Why are dopaminergic neurons particularly vulnerable?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:24.339025+00:00","updated_at":"2026-04-26T03:28:24.339025+00:00"},{"id":"open_question-876395d6-8620-4aa9-b47d-5d20ea669d4d","artifact_type":"open_question","title":"Temporal dynamics** — When does HS3ST2 upregulation occur relative to tau pathology?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:25:56.655387+00:00","updated_at":"2026-04-26T03:25:56.655387+00:00"},{"id":"open_question-2fdcf8ba-20f3-46d0-adb2-3f179e7a8564","artifact_type":"open_question","title":"Which microglial states are causally protective versus harmful at each disease stage?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:27.041478+00:00","updated_at":"2026-04-26T03:28:27.041478+00:00"},{"id":"open_question-2a0e3442-f059-45ab-a869-e8d74415a64e","artifact_type":"open_question","title":"Combination Strategies**: Which pharmacological agents synergize with exercise?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:07.273617+00:00","updated_at":"2026-04-26T03:27:07.273617+00:00"},{"id":"open_question-5250a9c9-d24a-436e-aa1b-8b873387362a","artifact_type":"open_question","title":"How should human trials operationalize tripartite endpoints beyond global cognition scales?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:38.633558+00:00","updated_at":"2026-04-26T03:28:38.633558+00:00"},{"id":"open_question-5f6ee0d0-6fbf-46fe-9ffb-f6deae5fc13a","artifact_type":"open_question","title":"Development**: What drives meningeal lymphatic development?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:11.477657+00:00","updated_at":"2026-04-26T03:29:11.477657+00:00"},{"id":"open_question-c2324596-f5d1-4df6-9b1e-a9a203b6bbdf","artifact_type":"open_question","title":"Regulation**: How are lymphatics regulated in the CNS?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:11.544181+00:00","updated_at":"2026-04-26T03:29:11.544181+00:00"},{"id":"open_question-2272f75f-2528-4317-9069-b256d7a6831f","artifact_type":"open_question","title":"Why do different diseases have different patterns?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:15.958849+00:00","updated_at":"2026-04-26T03:28:15.958849+00:00"},{"id":"open_question-38e26f64-4f2b-47f1-a3be-18881dbd7c83","artifact_type":"open_question","title":"Can propagation be stopped once started?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:16.033320+00:00","updated_at":"2026-04-26T03:28:16.033320+00:00"},{"id":"open_question-475645e0-2db6-41df-a189-3fa5979ba36d","artifact_type":"open_question","title":"What determines PSP-C vs. Richardson syndrome phenotype?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:28:16.289753+00:00","updated_at":"2026-04-26T03:28:16.289753+00:00"},{"id":"open_question-340bbca3-57bf-4fb8-b929-5f341a30d198","artifact_type":"open_question","title":"Timing**: When in disease course?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:44.381809+00:00","updated_at":"2026-04-26T03:29:44.381809+00:00"},{"id":"open_question-abceda22-4a30-40e7-8a4f-c9e2ca6100e1","artifact_type":"open_question","title":"Cell type**: Which cells drive changes?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:44.328031+00:00","updated_at":"2026-04-26T03:29:44.328031+00:00"},{"id":"open_question-3d912899-2516-49ac-bd36-b539cdca4b11","artifact_type":"open_question","title":"Therapeutic window**: When in disease course is intervention most effective?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:43.818981+00:00","updated_at":"2026-04-26T03:29:43.818981+00:00"},{"id":"open_question-da31ef53-558f-4cf5-b5ea-3f72e4cc9c54","artifact_type":"open_question","title":"Cell-type specificity**: What makes certain neurons more vulnerable?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:43.702941+00:00","updated_at":"2026-04-26T03:29:43.702941+00:00"},{"id":"open_question-c3b16a81-56e3-4616-8f64-54f333266daa","artifact_type":"open_question","title":"Primary vs. secondary excitotoxicity**: Is excitotoxicity a primary driver or downstream effect?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:43.639778+00:00","updated_at":"2026-04-26T03:29:43.639778+00:00"},{"id":"open_question-mechanisms-pd-dopamine-metabolism-836085b7","artifact_type":"open_question","title":"Genetic stratification","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-b37b2a74-05f3-4ca3-8f41-2393318a01cf","artifact_type":"open_question","title":"How do age-related changes in neurexin expression interact with protein aggregation pathologies in sporadic neurodegeneration?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:38.695984+00:00","updated_at":"2026-04-26T03:29:38.695984+00:00"},{"id":"open_question-628fca17-883f-427d-a7b0-0611bf13359f","artifact_type":"open_question","title":"Which specific neurexin splice isoforms are most dysregulated in each neurodegenerative disease, and can we selectively restore them?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:38.523117+00:00","updated_at":"2026-04-26T03:29:38.523117+00:00"},{"id":"open_question-e7015b8c-fe1d-4c34-a8b3-5f65ebdb47e1","artifact_type":"open_question","title":"Fission vs. fusion prioritization** — Which process is more critical to target?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:47.171402+00:00","updated_at":"2026-04-26T03:29:47.171402+00:00"},{"id":"open_question-53b299ad-42ec-4ec0-9a63-362506546741","artifact_type":"open_question","title":"Optimal intervention timing** — When during disease progression should fission be modulated?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:47.116142+00:00","updated_at":"2026-04-26T03:29:47.116142+00:00"},{"id":"open_question-360f5cce-cf84-45c7-b333-99daac37c107","artifact_type":"open_question","title":"Why are specific neurons vulnerable?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:47.062958+00:00","updated_at":"2026-04-26T03:29:47.062958+00:00"},{"id":"open_question-f6631d41-1e4d-4bc5-9fad-d379082e44b8","artifact_type":"open_question","title":"How do other PD genes (LRRK2, GBA, SNCA) interact with the DJ-1-PTEN-P53 network?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:38.385820+00:00","updated_at":"2026-04-26T03:29:38.385820+00:00"},{"id":"open_question-6fa34220-ba1c-4351-ae79-524f8a20a3b9","artifact_type":"open_question","title":"What is the role of neuronal activity-dependent oxidative stress in modulating this network?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:38.311738+00:00","updated_at":"2026-04-26T03:29:38.311738+00:00"},{"id":"open_question-cccaa5cc-90eb-4137-835d-0f95de173f93","artifact_type":"open_question","title":"Can we develop therapies that selectively enhance the PTEN-activating function of DJ-1 without affecting P53 stabilization?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:38.245442+00:00","updated_at":"2026-04-26T03:29:38.245442+00:00"},{"id":"open_question-888b57ec-2b00-4aa6-8b1f-c8366407f08b","artifact_type":"open_question","title":"What determines the threshold between protective and destructive P53 activation?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:38.183590+00:00","updated_at":"2026-04-26T03:29:38.183590+00:00"},{"id":"open_question-5eb99108-bcc5-4af2-b1de-4e459c115d7b","artifact_type":"open_question","title":"How do different cell types in the brain contribute to condensate pathology?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:38.068745+00:00","updated_at":"2026-04-26T03:29:38.068745+00:00"},{"id":"open_question-98a1542a-f24e-4b76-8a8e-b17d6feb6a92","artifact_type":"open_question","title":"What is the exact relationship between phase separation and traditional protein aggregation?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:38.015688+00:00","updated_at":"2026-04-26T03:29:38.015688+00:00"},{"id":"open_question-6f91b4d5-64e4-4a8f-bb8d-081dd295dcb6","artifact_type":"open_question","title":"Signaling specificity:** How is pathway specificity achieved?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:37.574604+00:00","updated_at":"2026-04-26T03:29:37.574604+00:00"},{"id":"open_question-72c3884b-b213-45e9-9862-09ef603b11cb","artifact_type":"open_question","title":"Ligand identification:** Complete ligand repertoire?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:37.518492+00:00","updated_at":"2026-04-26T03:29:37.518492+00:00"},{"id":"open_question-afb212c4-87f1-4b2d-89bd-4f273dd7995d","artifact_type":"open_question","title":"Off-target effects**: How to minimize impact on kidney and lung function?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:35.649386+00:00","updated_at":"2026-04-26T03:29:35.649386+00:00"},{"id":"open_question-16f63098-f6b1-47a1-b7c3-d1e5e9ef7c20","artifact_type":"open_question","title":"Non-motor symptoms**: Does LRRK2 inhibition help constipation, sleep disorders, anosmia?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:35.590532+00:00","updated_at":"2026-04-26T03:29:35.590532+00:00"},{"id":"open_question-c6569d69-2a2e-41bc-8746-f6fef8857fa1","artifact_type":"open_question","title":"Combination**: Should LRRK2 inhibitors combine with anti-alpha-synuclein therapies?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:35.532809+00:00","updated_at":"2026-04-26T03:29:35.532809+00:00"},{"id":"open_question-bb917df2-99a1-4b3e-a0a7-c24cad8233d7","artifact_type":"open_question","title":"Timing**: Pre-symptomatic vs. symptomatic intervention — which is more effective?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:35.478049+00:00","updated_at":"2026-04-26T03:29:35.478049+00:00"},{"id":"open_question-ad98882f-ae10-455c-9c22-716a40dc9c2f","artifact_type":"open_question","title":"Population selection**: Should therapy target all PD, only LRRK2 mutation carriers, or all with elevated LRRK2 activity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:35.422852+00:00","updated_at":"2026-04-26T03:29:35.422852+00:00"},{"id":"open_question-6a9df73d-c9ce-4987-ba6a-7ad5aae43d64","artifact_type":"open_question","title":"Optimal dosing**: What level of kinase inhibition is needed vs. tolerated?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:35.365677+00:00","updated_at":"2026-04-26T03:29:35.365677+00:00"},{"id":"open_question-mechanisms-tam-receptor-signaling-c3292c5a","artifact_type":"open_question","title":"Cell-type specificity:","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-tam-receptor-signaling-64a449f8","artifact_type":"open_question","title":"Temporal dynamics:","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-tam-receptor-signaling-99e8c5f8","artifact_type":"open_question","title":"Species differences:","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-tam-receptor-signaling-d8486eda","artifact_type":"open_question","title":"Target validation:","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-tam-receptor-signaling-f7bff00b","artifact_type":"open_question","title":"Therapeutic window:","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-tam-receptor-signaling-dcd69c3f","artifact_type":"open_question","title":"Combination approaches:","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-tam-receptor-signaling-a1e8cedb","artifact_type":"open_question","title":"Single-cell proteomics:","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-f623d60b-f813-4d7c-8d2e-e6ea8b2ef47d","artifact_type":"open_question","title":"What are optimal therapeutic targets?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:36.800971+00:00","updated_at":"2026-04-26T03:29:36.800971+00:00"},{"id":"open_question-fb058436-0ba2-473c-80e0-06ccae06ffaf","artifact_type":"open_question","title":"Can antiretroviral therapy meaningfully impact disease?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:36.742762+00:00","updated_at":"2026-04-26T03:29:36.742762+00:00"},{"id":"open_question-ce6e8b01-016d-46f5-8b50-983351c53e1a","artifact_type":"open_question","title":"What triggers HERV activation in disease?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:36.672988+00:00","updated_at":"2026-04-26T03:29:36.672988+00:00"},{"id":"open_question-132d867c-659f-4561-8337-bb659fbe544f","artifact_type":"open_question","title":"Which HERV elements are truly pathogenic?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:36.602165+00:00","updated_at":"2026-04-26T03:29:36.602165+00:00"},{"id":"open_question-5c19847f-df63-4378-a9aa-e338b8ce2f53","artifact_type":"open_question","title":"Cell-type mechanisms**: How does the same axis produce opposite effects in neurons versus glia?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:19.169433+00:00","updated_at":"2026-04-26T03:29:19.169433+00:00"},{"id":"open_question-24faebda-d367-4733-b6ff-401aad7052f6","artifact_type":"open_question","title":"Temporal dynamics**: When does axis dysregulation begin relative to tau pathology?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:19.050728+00:00","updated_at":"2026-04-26T03:29:19.050728+00:00"},{"id":"open_question-mechanisms-pd-dopamine-metabolism-bd8695ef","artifact_type":"open_question","title":"Personalized dosing","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-3f0afbdc-d34c-4d0b-bdd9-fdc18258ece7","artifact_type":"open_question","title":"Causality**: Does ETC dysfunction initiate or result from neurodegeneration?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:18.580606+00:00","updated_at":"2026-04-26T03:29:18.580606+00:00"},{"id":"open_question-ee178f24-6188-4a2a-af65-5d54bf182774","artifact_type":"open_question","title":"What determines the balance between amyloidogenic and non-amyloidogenic APP processing in neurons?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:46.175545+00:00","updated_at":"2026-04-26T03:29:46.175545+00:00"},{"id":"open_question-2aec9200-d146-41b8-9af7-03b67c710c69","artifact_type":"open_question","title":"Combination approaches**: Optimal treatment combinations?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:18.477517+00:00","updated_at":"2026-04-26T03:29:18.477517+00:00"},{"id":"open_question-12aaffc1-6ce1-407d-bbaf-e34207d04456","artifact_type":"open_question","title":"How does Fe65 phosphorylation regulate complex formation in vivo?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:46.119940+00:00","updated_at":"2026-04-26T03:29:46.119940+00:00"},{"id":"open_question-f5c02bab-1ece-4e21-9226-a560035bca7d","artifact_type":"open_question","title":"Therapeutic window**: What level of GCase restoration is needed?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:18.422677+00:00","updated_at":"2026-04-26T03:29:18.422677+00:00"},{"id":"open_question-5d89bdd4-b6d5-4dbc-91b5-00e92d729614","artifact_type":"open_question","title":"Can we develop substrate-selective inhibitors that spare essential BACE1 functions?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:46.057756+00:00","updated_at":"2026-04-26T03:29:46.057756+00:00"},{"id":"open_question-94c59ce0-b7f1-43f0-83de-a1359468ceb0","artifact_type":"open_question","title":"Penetrance modifiers**: What determines which carriers develop PD?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:18.309814+00:00","updated_at":"2026-04-26T03:29:18.309814+00:00"},{"id":"open_question-76b9e7e9-562d-4641-8a54-500b9c54a331","artifact_type":"open_question","title":"What is the complete inventory of BACE1 substrates, and how does chronic inhibition affect their function?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:45.997512+00:00","updated_at":"2026-04-26T03:29:45.997512+00:00"},{"id":"open_question-96717292-ffd9-4af5-a6f1-e6eabcf4e888","artifact_type":"open_question","title":"Therapeutic window**: What is the optimal activation level?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:45.942032+00:00","updated_at":"2026-04-26T03:29:45.942032+00:00"},{"id":"open_question-c922c276-f827-4b66-8b43-4efa1d677b02","artifact_type":"open_question","title":"How do TNTs interact with other transfer mechanisms?**: What is the relationship between TNTs and extracellular vesicles?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:33.447826+00:00","updated_at":"2026-04-26T03:29:33.447826+00:00"},{"id":"open_question-7652d163-5f04-4dd5-9a61-79ff0ee070ae","artifact_type":"open_question","title":"What determines TNT specificity?**: Why do some cells form TNTs while others do not?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:33.328540+00:00","updated_at":"2026-04-26T03:29:33.328540+00:00"},{"id":"open_question-c0d5f18b-4aa8-4737-a881-2eec001a7619","artifact_type":"open_question","title":"Therapeutic translation**: Can preclinical findings be successfully translated into effective clinical therapies?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:31.589741+00:00","updated_at":"2026-04-26T03:29:31.589741+00:00"},{"id":"open_question-e4f4e255-729b-4ecc-a4f6-ba3e06222709","artifact_type":"open_question","title":"Interrelationship with other proteinopathies**: How does TDP-43 pathology interact with other pathological proteins (tau, alpha-synuclein)?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:31.512290+00:00","updated_at":"2026-04-26T03:29:31.512290+00:00"},{"id":"open_question-daa5cea2-144d-432b-8d21-3a4662758d79","artifact_type":"open_question","title":"Strain heterogeneity**: How do distinct TDP-43 conformational strains influence clinical phenotypes?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:31.425880+00:00","updated_at":"2026-04-26T03:29:31.425880+00:00"},{"id":"open_question-mechanisms-lewy-body-formation-4fe43ad5","artifact_type":"open_question","title":"Immunotherapies","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-lewy-body-formation-b9fdf5b0","artifact_type":"open_question","title":"Oligomer breakers","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-lewy-body-formation-e3ca0ff5","artifact_type":"open_question","title":"Cell replacement","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-e089b462-54b0-41cc-bb3d-06e4528db712","artifact_type":"open_question","title":"Mechanisms of aggregation initiation**: What triggers the initial misfolding and aggregation of TDP-43 in sporadic cases?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:31.341028+00:00","updated_at":"2026-04-26T03:29:31.341028+00:00"},{"id":"open_question-mechanisms-mitochondrial-dysfunction-pathway-7638c539","artifact_type":"open_question","title":"mtDNA editing","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-mitochondrial-dysfunction-pathway-88d0ca18","artifact_type":"open_question","title":"Gene therapy","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-hedgehog-signaling-pathway-78ad4d19","artifact_type":"open_question","title":"Combination Therapy","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-epigenetic-clocks-brain-aging-359a20fa","artifact_type":"open_question","title":"Multi-omics integration","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-gba1-gcase-lysosome-pd-causal-chain-a34c665f","artifact_type":"open_question","title":"Optimal intervention timing?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-neurogenesis-ad-superagers-ad69b1b6","artifact_type":"open_question","title":"Mechanistic Studies","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-tau-seeding-propagation-pathway-df5a6472","artifact_type":"open_question","title":"Tau cryo-EM","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-tau-seeding-propagation-pathway-094d4dc3","artifact_type":"open_question","title":"Synthetic biology","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-centrosome-c5dcf2c4","artifact_type":"open_question","title":"Therapeutic targeting","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-psp-oral-health-dental-manifestations-88d0ca18","artifact_type":"open_question","title":"Gene therapy","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-psp-oral-health-dental-manifestations-95c88564","artifact_type":"open_question","title":"Neuromodulation","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-psp-therapeutic-response-monitoring-3edbe3c3","artifact_type":"open_question","title":"Phenotype-stratified","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-psp-therapeutic-response-monitoring-45d49608","artifact_type":"open_question","title":"Biomarker-driven","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-tunneling-nanotubes-7e108ff7","artifact_type":"open_question","title":"What determines TNT specificity?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-mechanisms-tunneling-nanotubes-600a6c6e","artifact_type":"open_question","title":"Can TNTs be therapeutically targeted?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-ccc7ad13-022a-4e84-b602-0e3bcef59981","artifact_type":"open_question","title":"Therapeutic**: Optimal intervention point?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:44.438995+00:00","updated_at":"2026-04-26T03:29:44.438995+00:00"}],"total":1203,"limit":100,"offset":0,"returned":100,"sort":"importance_elo","field":"mechanisms"}